Diabetes and cardiovascular disease

Diabetes, Obesity and Metabolism

Volumn 5, Issue SUPPL. 1, 2003, Pages s11-s18

  Neil, Andrew ^a,b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b CHURCHILL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACETYLSALICYLIC ACID; ALBUMIN; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; GLUCOSE; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LOW DENSITY LIPOPROTEIN; METFORMIN; PLACEBO; PRAVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ALBUMIN BLOOD LEVEL; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DIABETIC MICROANGIOPATHY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EPIDEMIC; FATALITY; GLUCOSE BLOOD LEVEL; GLUCOSE INTOLERANCE; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; LIFESTYLE; LIPOPROTEIN BLOOD LEVEL; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PREVALENCE; PRIMARY PREVENTION; RISK FACTOR; SECONDARY PREVENTION; TRIACYLGLYCEROL BLOOD LEVEL; UNITED KINGDOM;

EID: 0344465917     PISSN: 14628902     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1462-8902.2003.0311.x     Document Type: Article

References (61)

1. Rayner M, Petersen S, Buckley C et al. Coronary Heart Disease Statistics: Diabetes. London, UK: British Heart Foundation, 2001, Suppl.
2. Metcalfe MA, Baum JD. Incidence of insulin dependent diabetes in children aged under 15 years in the British Isles during 1988. BMJ 1991; 302: 443-447.
3. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 1998; 21: 1414-1431.
4. Department of Health. National Service Framework for Diabetes: Standards. London, UK: Stationery Office, 2001.
5. Riste L, Khan F, Cruickshank K. High prevalence of type 2 diabetes in all ethnic groups, including Europeans, in a British inner city: relative poverty, history, inactivity, or 21st century Europe? Diabetes Care 2001; 24: 1377-1383.
6. National Obesity Forum. The National Obesity Forum Primary Care Award for Excellence in Weight Management. http://www.nationalobesityforum.org.uk/completepack.htm
7. Fagot-Campagna A, Pettitt DJ, Engelgau MM et al. Type 2 diabetes among North American children and adolescents: an epidemiologic review and a public health perspective. J Pediatr 2000; 136: 664-672.
8. Chan JM, Rimm EB, Colditz GA et al. Obesity, fat distribution, and weight gain as risk factors for clinical diabetes in men. Diabetes Care 1994; 17: 961-969.
9. Knowler WC, Pettitt DJ, Savage PJ et al. Diabetes incidence in Pima Indians: contributions of obesity and parental diabetes. Am J Epidem Iol 1981; 113: 144-156.
10. Manson JE, Nathan DM, Krolewski AS et al. A prospective study of exercise and incidence of diabetes among US male physicians. JAMA 1992; 268: 63-67.
11. Ohlson L-O, Larsson B, Svardsudd K et al. The influence of body fat distribution on the incidence of diabetes mellitus: 13.5 years of follow-up of the participants of the study of men born in 1913. Diabetes 1985; 34: 1055-1058.
12. Després J-P, Nadeau A, Tremblay A et al. Role of deep abdominal fat in the association between regional adipose tissue distribution and glucose tolerance in obese women. Diabetes 1989; 38: 304-309.
13. Flier JS, Underhill LH. Non-insulin dependent diabetes mellitus - a genetically programmed failure of the beta cell to compensate for insulin resistance. N Engl J Med 1996; 334: 777-783.
14. Tuomilehto J, Lindström J, Eriksson JG et al. Prevention of Type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344: 1343-1350.
15. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393-403.
16. Hughes E. Screen savers. Diabetes Update, Summer. http://www.diabetes.org.uk/update/summer01/ssavers.htm
17. UK Prospective Diabetes Study Group. Study design, progress and performance. Diabetologia 1991; 34: 877-890.
18. Laing SP, Swerdlow AJ, Slater SD et al. The British Diabetic Association Cohort Study, I. all-cause mortality in patients with insulin-treated diabetes mellitus. Diabetic Med 1999; 16: 459-465.
19. Orchard TJ. From diagnosis and classification to complications and therapy. DCCT part II? Diabetes Care 1994; 17: 326-338.
20. Laing SP, Swerdlow AJ, Slater SD et al. The British Diabetic Association Cohort Study, II. Cause-specific mortality in patients with insulin-treated diabetes mellitus. Diabetic Med 1999; 16: 466-471.
21. Morrish NJ, Wang S-L, Stevens LK et al. Mortality and causes of death in the WHO multinational study of vascular disease in diabetes. Diabetologia 2001; 44 (Suppl. 2): S14-S21.
22. Burchfiel CM, Reed DM, Marcus EB et al. Association of diabetes mellitus with coronary atherosclerosis and myocardial lesions. An autopsy study from the Honolulu Heart Program. Am J Epidemiol 1993; 137: 1328-1340.
23. Wingard DL, Barrett-Connor E. Heart disease and diabetes. In: Harris M, ods. Diabetes in America. Bethesda, MD: National Institutes of Health, 1995: 429-448.
24. Nesto RW, Phillips RT. Asymptomatic myocardial ischemia in diabetic patients. Am J Med 1986; 80: 40-47.
25. Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham study. JAMA 1979; 241: 2035-2038.
26. Donnan PT, Boyle DIR, Broomhall J et al. Prognosis following first acute myocardial infarction in Type 2 diabetes: a comparative population study. Diabetic Med 2002; 19: 448-455.
27. Haffner SM, Lehto S, Ronnemaa T et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229-234.
28. Evans JMM, Wang J, Morris AD. Comparison of cardiovascular risk between patients with type 2 diabetes and those who had had a myocardial infarction: cross sectional and cohort studies. BMJ 2002; 324: 939-942.
29. Turner RC, Millns H, Neil HAW et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom prospective diabetes study (UKPDS. 23). BMJ 1998; 316: 823-828.
30. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7-22.
31. The DECODE Study Group, on behalf of the European Diabetes Epidemiology Group. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 2001; 161: 397-405.
32. Grundy SM, Benjamin IJ, Burke GL et al. Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 1999; 100: 1134-1146.
33. Packard Q. LDL subfractions and atherogenicity: an hypothesis from the University of Glasgow. Curr Med Res Opin 1996; 13: 379-390.
34. Austin MA, Edwards KL. Small, dense low density lipoproteins, the insulin resistance syndrome and noninsulin-dependent diabetes. Curr Opin Lipidol 1996; 7: 167-171.
35. Stamler J, Vaccaro O, Neaton JD et al. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993; 16: 434-444.
36. Fuller JH, Stevens LK, Wang S-L et al. Risk factors for cardiovascular mortality and morbidity: the WHO multinational study of vascular disease in diabetes. Diabetologia 2001; 44 (Suppl. 2): S54-S64.
37. Adler AI, Stratton IM, Neil HAW et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 2000; 321: 412-419.
38. Hayden JM, Reaven PD. Cardiovascular disease in diabetes mellitus type 2: a potential role for novel cardiovascular risk factors. Curr Opin Lipidol 2000; 11: 519-528.
39. Sunayama S, Watanabe Y, Daida H et al. Thiazolidinediones, dyslipidaemia and insulin resistance syndrome. Curr Opin Lipidol 2000; 11: 397-402.
40. Ginsberg HN. Insulin resistance and cardiovascular disease. J Clin Invest 2000; 106: 453-458.
41. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
42. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317: 703-713.
43. Hansson L, Zanchetti A, Carruthers SG et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351: 1755-1762.
44. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317: 703-713.
45. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000; 355: 253-259.
46. Shepherd J, Cobbe SM, Ford I et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301-1307.
47. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-1389.
48. Sacks FM, Pfeffer MA, Moye LA et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001-1009.
49. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349-1357.
50. Downs JR, Clearfield M, Weis S et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA 1998; 279: 1615-1622.
51. Yusuf S. Two decades of progress in preventing vascular disease. Lancet 2002; 360: 2-3.
52. Rubins HB, Robins SJ, Collins D et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 1999; 341: 410-418.
53. Rubins HB, Robins SJ, Collins D et al. Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs High-Density Lipoprotein Intervention Trial (VA-HIT). Arch Intern Med 2002; 162: 2597-2604.
54. University of Sydney Uninews. Heart drug trial reaches half way. http://www.usyd.edu.au/publications/news/2405News/2405_heart.html
55. Action to Control Cardiovascular Risk in Diabetes. http://www.accordtrial.org/public/purpose.cfm
56. Calhoun HM, Thomason MJ, Mackness MI et al. Design of the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with type 2 diabetes. Diabet Med 2002; 19: 201-211.
57. CARDS atorvastatin in diabetes trail halted early. Prac Diabetes Int 2003; 20: 230.
58. Wood D, Durrington P, Poulter N et al. Joint British recommendations on prevention of coronary heart disease in clinical practice. Heart 1998; 80 (Suppl. 2): S1-S29.
59. National Institute of Clinical Excellence. Management of Type 2 Diabetes: Management of blood pressure and blood lipids; Inherited Clinical Guideline H. http://www.nice.org.uk/pdf/NICE_INHERITEd_Hv8.pdf
60. Department of Health. National Service Framework for Coronary Heart Disease. London, UK: Stationery Office, 2000.
61. Boyle R. DoH explains thinking behind national service framework for coronary heart disease. BMJ 2000; 321: 1083.